Citadel Advisors
NEXI

Citadel Advisors’s NexImmune, Inc. Common Stock NEXI Stock Holding History

Citadel Advisors’s Portfolio NEXI Stock Details NEXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,693
Closed -$68K – 13863
2022
Q2 		$68K Buy
+1,693
New +$105K ﹤0.01% 11729

Other funds holding NEXI

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
AO
Allen Operations New York $670M AUM 26.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
KHCM
Kettle Hill Capital Management New York $399M AUM 10.05% 1-Year Est. Return

Citadel Advisors's NEXI Position: Q3 2022 in Review

Citadel Advisors sold out of NexImmune, Inc. Common Stock (NEXI) in Q3 2022, closing a stake of 1,693 shares — an estimated $68K sold.

Citadel Advisors first reported a position in NEXI in Q2 2022 and held it in 1 quarter. The position peaked at $68K in Q2 2022. 38 funds tracked by Wall St. Rank hold NEXI as of Q3 2022.

  • Citadel Advisors reported no remaining NexImmune, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Citadel Advisors sold 1,693 NexImmune, Inc. Common Stock shares in Q3 2022, an estimated $68K.
  • Citadel Advisors first reported a position in NexImmune, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Citadel Advisors's NexImmune, Inc. Common Stock position peaked at $68K in Q2 2022.
  • 38 funds tracked by Wall St. Rank held NexImmune, Inc. Common Stock as of Q3 2022.

Based on Citadel Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.